You will be redirected to:
R&D activity is currently under mounting pressure from increasing competition and regulation.
Virginie Grosso, Associate General Manager France & Delivery Director – Keyrus Life Science, and Brigitte Marcheterre, General Manager Canada & USA – Keyrus Life Science, outline their vision.
R&D activity, which is essential to providing new medications and medical treatments, is currently under mounting pressure from increa- sing competition and regulation. How can digital be leveraged to combat these challenges? Virginie Grosso, Associate General Manager France & Delivery Director – Keyrus Life Science, and Brigitte Marcheterre, General Manager Canada & USA – Keyrus Life Science, outline their vision. R&D represents an industry pain point: cycles of 10 to 15 years, very little chance of success (the probability of obtaining regulatory approval once a molecule has been identified is 1 in 10,000!), the need for high numbers of pa- tients with a suitable profile, and the increasing complexity of clinical protocol (59% more certifications and 25% more patient visits in 10 years), makes it difficult to recruit pa- tients for trials. Public authorities appear to have decreasing funds avai- lable to invest in healthcare, despite increasing safety requirements and an expectation for ever-more effective medication. Now more than ever, the main challenges in clinical trials are delays, cost and quality.
The immediate advantage of digital technologies in this context is the access they provide to an incredibly rich pool of information. This improves decision-making regar- ding the efficiency and conduct of clinical trials. Typically, the creation of government databases of comprehensive, anonymous, electronic medical records allows trials to be conducted in a faster, more reliable, and – for the patients – more personalised manner. This data also allows us to measure the medication’s effectiveness in a real-world situation, and the patient’s quality of life. The second advantage concerns patient selection. Remem- ber, 80% of clinical trials do not recruit their target number of patients, and 50% of research centres only recruit one patient... By developing online recruitment using specialised platforms, we widen the net, increasing both the quality and quantity of potential candidates. Another use for data and digital in healthcare could be the analysis of patient experiences shared on social media. This indicator can be used, among other things, to enhance trials by offering the patient’s perspective, collect real- world data on the use of medication, and even identify misuse and prevent health crises. This incredible technological potential puts new responsi- bility on CROs to drive innovation among their customers, by combining traditional and digital expertise.
On the other hand, this potential is currently held back by a legal framework that lacks clarity. AI, Big Data, smart devices to be worn or implanted, and Blockchain as a means of gaining trust, each raise important legal and ethical questions. To whom does the data belong, how is it anonymised, how do we obtain patient consent, what is the share of responsibility between the doctor, the biotech that developed the algorithm, the algorithm, and so on? We are still grappling with these fundamental questions.
Stay updated on the latest articles, events, and more
Blog post
Nowadays, all companies active in the life science ecosystem consider data as a crucial asset to their success. Pharma companies are collecting more and more information during their clinical trials or commercial and medical activities. Clinical laboratories have to deploy complex data infrastructures to better serve their patients and clients, and Biotech and MedTech companies need to gather and analyze a lot of scientific and technical data.
Press release
Paris 9th January, 2023 (France) - Today, EvidentIQ, a leading clinical data science group and Keyrus Life Science, the international Connected Contract Research Organization (C²RO), announced the signing of a strategic partnership. The synergy between both companies will improve automation, efficiency and agility in clinical research by leveraging new eClinical capabilities.
Press release
Paris, Levallois-Perret, November 7th, 2022 - Keyrus Life Science and Parean Biotechnologies will join their expertise in data science and technologies to meet the most critical challenges for clients in the fields of biometry, biostatistics and bioinformatics.
Event
This summer was very busy and interesting for the Keyrus Life Science North America Team. We attended three pivotal life science conferences: Decentralized Clinical Trials Conference, BIO International Convention, and DIA Conference.
Press release
Paris, Levallois-Perret, June 23, 2022 - Keyrus Life Science announces the launch of its new visual identity strengthening its synergies with the Keyrus Group to address the most pressing challenges of its clients in the life science industry and to drive clinical research forward.
Expert's opinion
Digitalization, data and connectivity has become part of our daily lives in all its dimensions.
Expert's opinion
Clinical trials produce a massive amount of data. In most cases, the challenge lies less in the volume of data to process, but more in its diversity. The sources of data are indeed numerous and do not stop increasing.
Blog post
The World Heart Day, an occasion to remind us all, that cardiovascular diseases (CVD) causes more than 18 million of deaths per year.
Event
Today, September 21st, is the World Alzheimer’s Day, so let’s do a quick review of the investigated therapeutic targets to find a cure to this pathology
Event
Keyrus Life Science joined the Keyrus Foundation in the team sports challenge 'Connected against hunger'